9 big takeaways from the $74 billion Bristol-Celgene deal - STAT

9 big takeaways from the $74 billion Bristol-Celgene deal - STAT

STAT Plus: 9 big takeaways from the $74 billion Bristol-Celgene deal

By DAMIAN GARDE AND ADAM FEUERSTEIN AND ED SILVERMAN

ALEX HOGAN/STAT

The proposed merger of Bristol-Myers Squibb and Celgene have sweeping implications for the drug industry. Here are some of the major ones.

READ MORE